Latest Commercialisation News

Micro-X has secured an eight-month, US$0.75 million contract extension from the US Department of Homeland Security to upgrade its miniature CT baggage scanner for scaled manufacturing. The award advances a technology platform towards possible commercial use, but does not yet represent a product sale or customer deployment.

WhiteHawk has secured an unsecured A$1.5 million facility and says it does not currently expect to raise equity, after cutting annualised operating costs by about A$1.24 million. The funding comes at a 16% interest rate and must be repaid in full at maturity, leaving execution and cash receipts central to the plan.

AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

GCM Corporation’s FY26 report charts its shift from explorer to thermal-management manufacturer, with independent VHD validation, 44 products and first reported product sales. But the company remains loss-making, cash-burning and dependent on further funding, while its auditor warns of material uncertainty over going concern.

Prairie Lithium has moved its Saskatchewan project closer to commissioning, with Pad #1 construction advancing and Hydro Lithium agreeing to buy all Phase 1 output. The progress came alongside a A$3.46 million FY2026 loss, further equity issuance and a year-end cash balance of A$5.85 million.

Invictus Energy has entered FY2027 with A$10.89 million in cash and a funded November drilling target, but its annual report warns that further financing may be required to continue operations. The company also reported a wider A$6.54 million loss for FY2026.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

Adisyn has moved closer to commercialising its graphene platform after independently verified sub-300°C deposition, a US patent allowance and a new defence technology arm. The progress came alongside a A$7.83 million statutory loss, A$4.47 million in operating cash outflows and a heavily judgement-based A$42.1 million technology asset.

Cobalt Blue has cleared important technical and regulatory hurdles at its Kwinana refinery, but the pre-revenue developer says further funding is needed and auditors flagged material uncertainty over its ability to continue as a going concern. The company reported an A$8.797 million loss for FY2026 despite ending the year with A$4.265 million in cash.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.